Sector News

AstraZeneca Non-Executive Director Bruce Burlington to retire

August 17, 2017
Life sciences

AstraZeneca PLC on Wednesday said Non-Executive Director Bruce Burlington will retire from the board on August 31.

The FTSE 100-listed pharmaceutical said Burlington, who joined the board in 2010, will also step down as a member of the audit committee, the nomination and governance committee and from his role as chairman of the science committee.

Chairman Leif Johansson said: “Bruce has been an exemplary director who has made a significant contribution to the board’s work over many years. We have valued his insightful and frank participation as a board member, and chairman of the science committee during a period of innovation-led transformation at AstraZeneca.

“His diligence and commitment to the work of the audit committee and the nomination and governance committee should also be acknowledged.”

By Maryam Cockar

Source: Alliance News

Related News

October 24, 2020

Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?

Life sciences

LinkedIn Twitter Xing Facebook EmailDifferent from a gluten intolerance, coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are […]

October 24, 2020

Bone Therapeutics showcases allogeneic cell therapy data

Life sciences

LinkedIn Twitter Xing Facebook EmailBone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures. […]

October 24, 2020

UCB acquires new campus to support UK operations

Life sciences

LinkedIn Twitter Xing Facebook EmailBelgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK. The acquisition of the site in Windlesham, […]

Send this to a friend